The world's first oral hexavalent rotavirus vaccine debuts in Wuhan, expected to be available for vaccination by the end of the month.
According to Hubei News, on December 13, the world's first oral hexavalent reassortant rotavirus live vaccine (Vero cells) developed by the Wuhan Institute of Biological Products was unveiled in Wuhan, and it is expected to be administered as early as the end of December this year. Rotavirus is not only the most important pathogen causing severe diarrhea in infants and young children but also the leading cause of diarrhea-related deaths in children under five worldwide. The newly launched hexavalent rotavirus vaccine took 18 years from research and development to production, and it is also administered orally. It can effectively prevent diarrhea caused by six serotypes: G1, G2, G3, G4, G8, and G9, with a particular focus on the significantly rising G8 and G9 types in recent years, achieving full coverage of the currently dominant G-type strains in our country for the first time. This fills the gap in the previous imported vaccines that inadequately protected against the highly prevalent G8 strain in Asia, providing a 'Chinese solution' for the prevention and control of autumn diarrhea in infants and young children worldwide. #加密市场观察 $MOVE
{spot}(MOVEUSDT)
{spot}(FISUSDT)
